Supporting Global and UK pharma with early dialogue in the UK and France


  • Top 20 pharma company, Global, UK and France market access teams



  • Phase 2/3 protocol finalisation timings meant that NICE and HAS advice was required by the R&D team within months
  • Delivering the first phase of the project – a briefing book to NICE by early April 2020 – during the initial months of COVID



  • redthread worked closely as a key part of the 4-person core project team to research, write and ultimately deliver a comprehensive briefing book to NICE from a kick off in late December to submission in early April
  • A clear outline, and detailed and accurate first draft enabled the team to focus internal conversations on stakeholder management and clearly defining questions and company positions
  • redthread supported all internal stakeholder conversations, and in many cases were trusted to liaise directly with key global R&D colleagues on behalf of the project team



  • Exceptionally high-quality dossier submitted to NICE for which only two clarification questions were received
  • Our client commissioned us for a follow-up project supporting early dialogue with HAS for the same asset in a different indication


“I think it’s fair to say that the number of questions asked really reflects the quality of the briefing book we submitted – really well done guys”

UK Market Access Manager, Top 20 pharma

“You guys are the best!!!”

Global Value & Access Lead, Top 20 pharma